Fusion proteins
AssigneeGlaxo Wellcome Inc.
InventorsSusan Elizabeth Newton, Berwyn Ewart Clarke
Life of this patent
Estimating the term…
Abstract
A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.
Claims17
A DNA sequence encoding a fusion protein which comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system.
A eucaryotic expression vector comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system.
A eucaryotic host cell comprising a vector comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said host cell expresses said fusion protein on the surface thereof and presents said epitope in a manner recognizable by an immune system.
A eucaryotic plasmid expression vector compatible with a yeast host comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system.
A yeast host comprising a vector compatible with said host, comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system, and wherein said host expresses said fusion protein.
Dependencies are inferred from the claim text.